Resource Allocation Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Why does resource allocation need to take place?

A

Resources are scarce and could be used in many ways. Ethics: needs to be clear and explicit about what we are trying to achieve and who benefits from public expenditure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is implicit rationing?

A

Implicit rationing is the allocation of resources through individual clinical decisions without the criteria for those decisions being explicit.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the flaws of implicit rationing?

A

Can lead to inequities and discrimination, is open to abuse, decision based on perceptions of social deservingness and doctors are generally increasingly unwilling to do it.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is explicit rationing?

A

Explicit health care rationing or priority-setting is the use of institutional procedures for the systematic allocation of resources within health care system. Care is limited and the decisions are explicit, as is the reasoning behind those decisions. Technical processes – e.g. Assessments of efficiency and equity. Political processes – e.g. Lay participation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the advantages and disadvantages of explicit rationing?

A

Advantages: Transparent, accountable, Opportunity for debate, More clearly evidence-based, More opportunities for equity in decision-making

Disadvantages: Very complex, Heterogeneity of patients and illnesses, Patient and professional hostility, Impact on clinical freedom, Some evidence of patient distress.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the purpose of NICE?

A

Set up to ‘enable evidence of clinical and cost effectiveness to be integrated to inform a national judgement on the value of a treatment(s) relative to alternative uses of resources’
Provides guidance on whether treatments (new or existing) can be recommended for use in the NHS in England. NICE is asked to appraise significant new drugs and devices to help make sure that effective and cost effective products are made available to patients quickly and to minimise variations in the available of treatments.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the issues with NICE approving and not approving treatments?

A

If not approved, patients are effectively denied access to them (except for individual requests). If approved, local NHS organisations must fund them (if clinically appropriate), sometimes with adverse consequences for other priorities.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Define scarcity, efficiency, equity, effectiveness and utility?

A

Scarcity: Need outstrips resources. Prioritisation is inevitable
Efficiency: Getting the most out of limited resources
Equity: The extent to which distribution of resources is fair
Effectiveness: The extent to which an intervention produces desired outcomes
Utility: The value an individual places on a health state

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is opportunity cost?

A

Opportunity Cost: Once you have used a resource in one way, you no longer have it to use in another way. When deciding to spend resources on a new treatment, those resources cannot now be used on other treatments. The opportunity cost of the new treatment is the value of the next best alternative use of those resources. – Cost is viewed as sacrifice rather than financial expenditure. Opportunity cost is measured in benefits foregone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the difference between technical efficacy and allocative efficacy?

A

Technical efficiency – you are interested in the most efficient way of meeting a need (e.g. should antenatal care be community or hospital-based?). Allocative efficiency – you are choosing between the many needs to be met (e.g. fund hip replacements or neonatal care?).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is economic evaluation?

A

Comparison of resource implications and benefits of alternative ways of delivering healthcare. Can facilitate decisions so that they are more transparent and fair.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How can we measure costs?

A

Identify, quantify and value resources needed
Categories of costs: – Costs of the healthcare services – Costs of the patient’s time – Costs associated with care-giving – Other costs associated with illness – Economic costs borne by the employers, other employees and the rest of society.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How do we measure benefits?

A

Benefits are harder to measure. Improved (or maintained) health hard to value. Categories of benefits/consequences: – Impact on health status (in terms of survival or quality of life or both); – Savings in other healthcare resources (such as drugs, hospitalisations, procedures, etc.) if the patient’s health state is improved – Improved productivity if patient, or family members, returns to work earlier.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the cost minimisation analysis?

A

Outcomes assumed to be equivalent. Focus is on costs (i.e. only the inputs). Not often relevant as outcomes rarely equivalent. Possible example: – Say all prostheses for hip replacement improve mobility equally. Choose the cheapest one.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is cost effectiveness analysis?

A

Used to compare drugs or interventions which have a common health outcome e.g. reduction in blood pressure. Compared in terms of cost per unit outcome e.g. cost per reduction of 5mm/Hg. If costs are higher for one treatment, but benefits are too, need to calculate how much extra benefit is obtained for the extra cost. Key question: Is extra benefit worth extra cost?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is cost benefit analysis?

A

All inputs and outputs valued in monetary terms. Can allow comparison with interventions outside healthcare. Methodological difficulties e.g. putting monetary value on non-monetary benefits such as lives saved. “Willingness to pay” often used, but this is also problematic.

17
Q

What is cost utility analysis?

A

Cost utility analysis focuses on quality of health outcomes produced or foregone. Most frequently used measure is quality adjusted life year (QALY). Interventions can be compared in cost per QALY terms.

18
Q

Why use QALY’s?

A

To use cost-effectiveness as a guide to decision-making, we need to compare the cost-effectiveness of different uses of resources. Therefore we need an effectiveness measure that can be used in a wide range of settings: Life-years gained (but only where survival is main outcome) and Quality adjusted life years (QALYs) (Composite of survival and quality of life).

19
Q

How are QALY’s calculated?

A

QALYs adjust life expectancy for quality of life. 1 year of perfect health = 1 QALY. Assumes that 1 year in perfect health = 10 years with a quality of life of 0.10 perfect health. Quality of life is measured using the EQ-5D. Don’t forget to calculate the cost of the treatmemt.

20
Q

What alternatives are there to QALY?

A

Alternatives to QALYs
The QALY has attracted considerable controversy. You may see alternatives – Health Year Equivalents (HYEs) – Saved-young-life equivalents (SAVEs) – Disability Adjusted Life Years (DALYs). Advantages and disadvantages to all but NICE uses QALYs.

21
Q

How do NICE intergrate cost into QALY?

A

To assess cost-effectiveness, the QALY score is integrated with the price of treatment. The result is a ‘cost per QALY’ figure, which allows NICE to determine the cost-effectiveness of the treatment.

Below £20K per QALY technology will normally be approved. £20 - £30K judgements will take account of: – Degree of uncertainty – If change in HRQoL is adequately captured in the QALY – Innovation that adds demonstrable and distinctive benefits not captured in the QALY. Above £30K need an ‘increasingly stronger case’.

22
Q

Why does NICE come into problems with the use of QALY?

A

May be resented by patient groups and pharmaceutical companies. CCGs prioritise NICE-approved interventions, sometimes with unintended consequences. Concerns about political interference.

23
Q

What criticisms are there of QALY?

A

Controversy about the values they embody. Do not distribute resources according to need, but according to the benefits gained per unit of cost. May disadvantage common conditions. Technical problems with their calculations. QALYs may not embrace all dimensions of benefit; values expressed by experimental subjects may not be representative. QALYs do not assess impact on carers or family.

More problems with QALYs
RCT evidence is not perfect – Comparison therapies may differ – Length of follow-up – Atypical care – Atypical patients – Limited generalisability – Sample sizes. Statistical modelling can address some problems and areas of uncertainty.